普略医学深耕转化医学与临床研究咨询十余年，汇聚临床医学专家、基础医学专家与生物医药科学与技术专家，服务覆盖转化医学、IIT（研究者发起的研究）、IND 申报与临床 I / II / III / IV 期试验、上市后临床研究、CGT（细胞与基因治疗）等。我们为 VC、PE 与天使投资机构、新药研发公司、生物医药企业战略发展部门提供高质量医学专家访谈与医学咨询服务——从投研尽调到临床开发，帮助您把不确定性变成可决策的洞察。
PoolingMed has spent over a decade focused on translational medicine and clinical research consulting, drawing on clinical medicine experts, basic medical scientists, and biopharmaceutical science & technology experts. Our services cover translational medicine, investigator-initiated trials (IIT), IND filings and Phase I / II / III / IV clinical trials, post-marketing studies, and cell & gene therapy (CGT) — serving VC / PE / angel investors, drug developers and strategy teams of biopharma companies, from investment diligence to clinical development.
了解专家咨询业务 Expert Consulting English Introduction（英文版专家咨询介绍）→面向 VC / PE / 天使投资机构、新药研发公司与生物医药企业战略发展部门，覆盖从靶点发现到上市后研究的全生命周期——从实验室发现到临床验证，从 IND 申报到各期临床试验，从注册到真实世界证据。
For VC / PE / angel investors, drug developers and strategy teams — covering the full lifecycle from target discovery to post-marketing: bench-to-clinic translation, IND filings, Phase I–IV trials, and real-world evidence.
肿瘤、自免、代谢等重点科室的核心研究中心主任与头部 KOL，覆盖各期临床试验的一线研究者。Leading investigators and key opinion leaders at China's core research centers — frontline clinical trial experience across Phase I–IV.
医学高校与科研院所的 PI 与转化研究团队，从机制研究到概念验证的深度科学论证。PIs and translational research teams from medical universities and institutes — deep scientific validation from mechanism studies to proof of concept.
药企研发、CXO 与技术平台的资深专家，覆盖 CMC、药械组合、CGT 等前沿方向的工程与产业经验。Senior experts from pharma R&D, CXOs and technology platforms — engineering and industry experience across CMC, drug-device combinations and CGT.
实验室发现 → 临床验证路径
Bench discovery → clinical validation
临床前证据梳理与注册路径
Preclinical evidence & regulatory path
首试人体 · 药代与耐受性
First-in-human · PK & tolerability
关键试验设计与证据生成
Pivotal trial design & evidence
上市后研究与真实世界证据
Post-marketing & real-world evidence
从实验室发现到临床验证：生物标志物策略、转化研究设计、概念验证（PoC）路径与跨学科专家论证。Bench-to-clinic translation: biomarker strategy, translational study design, proof-of-concept pathways and cross-disciplinary expert validation.
IND 申报前证据梳理与注册路径讨论，I 期试验（首试人体、剂量递增、PK/PD）的医学咨询与专家论证。Pre-IND evidence synthesis and regulatory pathway discussion; medical consulting for Phase I trials (first-in-human, dose escalation, PK/PD).
关键试验的适应症与终点选择、方案设计评估、研究者资源与中心布局的医学咨询。Medical consulting for pivotal trials: indication and endpoint selection, protocol design review, investigator and site strategy.
上市后研究与真实世界研究（RWS）的设计咨询、适应症拓展论证与药物警戒相关的医学支持。Design consulting for post-marketing and real-world studies (RWS), label-expansion rationale and pharmacovigilance-related medical support.
IIT 的研究设计优化、可行性评估、合规路径与研究中心/研究者匹配，十余年一线项目经验沉淀。IIT protocol optimization, feasibility assessment, compliance pathways and site/investigator matching — a decade of hands-on experience.
细胞与基因治疗项目的转化评估、试验设计要点、中国注册与研究中心格局咨询。Translational assessment of cell & gene therapy programs, trial-design considerations, and the Chinese regulatory and site landscape.
面向天使轮投资机构与创新科技专利技术交易：对标的技术的关键数据与技术参数进行独立的湿实验验证与复现，出具专业验证报告——让投资与交易决策建立在可复核的实验证据之上。For angel-round investors and innovative technology / patent transactions: independent wet-lab validation and replication of key data and technical parameters of the target technology, delivered with a professional validation report — so investment and deal decisions rest on verifiable experimental evidence.
当 AI 把药物发现压缩到「小时」级，真正的瓶颈转移到了验证端——湿实验与临床验证仍以「月·年」计，且 AI 设计分子的 I 期成功率约为行业基准的两倍、II 期却与行业持平。普略医学以十余年湿实验与临床研究积累，为 AI for Science 团队、投资机构与创新技术持有方提供「干湿闭环」的转化医学咨询：用计算提出假设，用湿实验验证与复现，让「干预-表型」数据回流模型。
AI has compressed drug discovery to hours — but validation still takes months to years, and while AI-designed molecules double Phase I success rates, Phase II remains flat. The bottleneck has moved to the wet lab. Drawing on a decade of hands-on wet-lab and clinical research capability, PoolingMed provides "dry-wet closed-loop" translational consulting for AI-for-Science teams, investors and technology holders: hypotheses proposed by computation, validated and replicated in the wet lab, with interventional-phenotype data flowing back into the models.
为 AI 模型预测设计湿实验验证方案：分子、靶点与机制的实验验证与数据复现，产出可回流模型的「干预-表型」数据资产。Wet-lab validation protocols for model predictions: experimental verification and data replication for molecules, targets and mechanisms — producing interventional-phenotype data assets that feed back into models.
评估 AI 设计分子与靶点的转化价值：成药性判断、适应症选择、PoC 路径与 IND / IIT 转化路径咨询——「I 期翻倍，II 期才是试金石」的冷静视角。Assessing the translational value of AI-designed molecules and targets: druggability, indication selection, PoC pathways and IND / IIT routes — with the sober view that Phase II, not Phase I, is the touchstone.
由普略 CEO / CSO 郭磊博士（曾任浙江大学医学院病理生理学教授、哈佛医学院遗传学系博士后）领衔的专家团队，提供 AI for Science 趋势研判与前瞻研究方向的评估论证（含「唯波生物学」等原创假说）。A scientific advisory team led by Dr. Lei Guo (PoolingMed CEO/CSO; formerly Professor of Pathophysiology at Zhejiang University School of Medicine and postdoctoral fellow at Harvard Medical School), providing trend analysis and assessment of forward-looking original research directions.
理论与实践输出：普略医学 CEO / CSO 郭磊博士受邀在第四届 CCF 数字医学大会 AI for Science 分论坛作主题演讲——《AI for Science：现状、未来和核心问题》。Thought leadership: Dr. Lei Guo, PoolingMed CEO / CSO, delivered the keynote "AI for Science: Status, Future and Core Questions" at the AI for Science Forum of the 4th CCF Digital Medicine Conference.
我们不追求专家库的规模数字。真正稀缺的，是在临床研究细分领域长期深耕所形成的专业判断、专家关系与项目 know-how。
We don't compete on database size. What is genuinely scarce is the judgment, the expert relationships and the project know-how built from years of hands-on work in clinical research.
我们不是「什么都做」的综合咨询公司。十余年来，普略只深耕转化医学与临床研究咨询——专注本身就是我们最大的差异化，也带来了跨治疗领域、跨开发阶段的专业判断力。We are not a generalist consulting firm. For more than ten years, PoolingMed has worked exclusively in translational medicine and clinical research consulting. That singular focus compounds into cross-therapeutic-area, cross-stage judgment.
依托十余年临床研究合作积累的一线专家关系，我们能在肿瘤、自免、代谢、CGT 等重点领域快速组织高质量专家访谈——覆盖核心研究中心与头部临床专家，而不是停留在泛泛的「行业内人士」。Years of hands-on clinical research collaboration have built first-line expert relationships across oncology, immunology, metabolic disease and CGT — enabling rapid access to leading investigators at China's core research centers.
与通用专家网络不同，普略团队具备医学与科研背景：我们理解您的科学问题，用专业语言设计访谈提纲、校验专家观点，交付的是可支撑决策的洞察，而不是仅有通话记录。Unlike generalist networks, our team has medical and scientific training. We understand your scientific questions, design interview guides in the right language, and validate expert input — delivering decision-ready insight, not just call logs.
以下为基于真实需求类型归纳的典型合作场景，用于说明我们的工作方式与交付价值。
Typical engagement scenarios illustrating how we work and what we deliver, based on recurring client needs.
评估一个处于临床阶段的中国创新药资产，需要验证其科学假设、临床数据质量与中国注册路径的真实风险。A clinical-stage Chinese drug asset must be validated: scientific hypothesis, quality of clinical data, and the true regulatory risk in China.
评估某候选药物的 IND 申报可行性、I 期设计要点与中国市场竞争格局。Assess IND readiness, Phase I design considerations and the Chinese competitive landscape for a new candidate.
已上市产品需要通过 IV 期研究与真实世界证据支持适应症拓展与市场准入。A marketed product needed Phase IV studies and real-world evidence to support label expansion and market access.
十余年积累的技术平台与业务体系——转化研发、企业学术服务、医院科室服务与试剂严选商城。
A decade of accumulated platforms and business lines — translational R&D, corporate academic services, hospital department services and a reagent marketplace.
我们的客户都面临同一个问题：重大决策背后，需要真实、专业的中国临床视角。Our clients share one problem: consequential decisions that need a real, professional view from China's clinical community.
投研阶段与投后管理的临床专家访谈需求，投前尽调与赛道评估。Expert interviews for investment research — diligence and sector evaluation.
IND 申报、各期临床试验设计与注册策略中的医学咨询需求。Medical consulting for IND filings, trial design and regulatory strategy.
BD 与管线决策所需的医学证据梳理与专家观点验证。Evidence synthesis and expert validation for BD and pipeline decisions.
告诉我们您正在评估的资产、面临的决策或计划开展的研究，我们将在 1 个工作日内回复，并签署保密协议后展开合作。
Tell us the asset you are evaluating, the decision you face, or the study you plan. We reply within one business day and sign an NDA before any engagement.
所有咨询默认在保密协议框架下进行。
All engagements are conducted under NDA by default.